Review of Cannabinoids for Multiple Sclerosis and the Emerging Field of Nano-Cannabinoid Medicine
This review highlights cannabinoids' potential as more than symptomatic treatment for MS, examining how nanotechnology may improve delivery.
Quick Facts
What This Study Found
Cannabinoids demonstrate anti-inflammatory, neuroprotective, and immunosuppressive properties relevant to MS. Nano-delivery systems may reduce toxicity.
Key Numbers
170 articles reviewed; CBD mechanisms: TNF-alpha downregulation, BDNF mRNA restoration, serotonin recovery
How They Did This
Narrative review of 170 articles from PubMed, Web of Science, and Scopus.
Why This Research Matters
MS has no universally effective treatment. Nanotechnology could overcome current limitations of cannabinoid medications.
The Bigger Picture
Cannabinoids as disease-modifying agents for MS is still largely theoretical. Nano-delivery is the next frontier.
What This Study Doesn't Tell Us
Narrative review. Mostly preclinical evidence. No new clinical data.
Questions This Raises
- ?Can nano-cannabinoids demonstrate superior efficacy in trials?
- ?What markers predict cannabinoid therapy response in MS?
Trust & Context
- Key Stat:
- CBD identified as antagonist against pro-inflammatory cytokines in MS
- Evidence Grade:
- Narrative review of mostly preclinical evidence.
- Study Age:
- Published in 2024.
- Original Title:
- Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine.
- Published In:
- Pharmaceutics, 16(2) (2024)
- Authors:
- Nouh, Roua A, Kamal, Ahmed, Oyewole, Oluwaseyi, Abbas, Walaa A, Abib, Bishoy, Omar, Abdelrouf, Mansour, Somaia T, Abdelnaser, Anwar
- Database ID:
- RTHC-05595
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
Could cannabinoids slow MS progression?
Preclinical evidence suggests potential but clinical trials are needed.
What is nano-cannabinoid medicine?
Nanotechnology-based cannabinoid delivery for reduced side effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05595APA
Nouh, Roua A; Kamal, Ahmed; Oyewole, Oluwaseyi; Abbas, Walaa A; Abib, Bishoy; Omar, Abdelrouf; Mansour, Somaia T; Abdelnaser, Anwar. (2024). Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine.. Pharmaceutics, 16(2). https://doi.org/10.3390/pharmaceutics16020241
MLA
Nouh, Roua A, et al. "Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine.." Pharmaceutics, 2024. https://doi.org/10.3390/pharmaceutics16020241
RethinkTHC
RethinkTHC Research Database. "Unveiling the Potential of Cannabinoids in Multiple Sclerosi..." RTHC-05595. Retrieved from https://rethinkthc.com/research/nouh-2024-unveiling-the-potential-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.